Are US pre-filing user fees in pharma's future?
This article was originally published in SRA
Executive Summary
When the US Food and Drug Administration negotiates with brand-name manufacturers on the next round of the Prescription Drug User Fee Act - PDUFA VI - the agency may try to find a way of receiving some payments earlier on in the drug development process, said Dr Gillian Woollett, senior vice president at Washington-based analysis and consultancy firm Avalere Health.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.